The efficacy of high-dose chemotherapy and the transplantation of autologous hemopoietic cells in lymphogranulomatosis
Mendeleeva, L.P.; Savchenko, V.G.; Rossiev, V.A.; Pavlova, O.A.; Aleksandrova, I.I.; Momotiuk, K.S.; Liubimova, L.S.; Kliasova, G.A.; Gribanova, E.O.; Demidova, I.A.; Kuliev, R.G.; Gal'tseva, I.V.; Kuz'mina, L.A.; Kaplanskaia, I.B.; Petrov, M.M.; Varlamova, S.V.; Shulutko, E.M.; Kulikov, S.M.
Terapevticheskii Arkhiv 72(7): 32-37
2000
ISSN/ISBN: 0040-3660 PMID: 10983318 Document Number: 525574
To determine clinical effectiveness of high-dose polychemotherapy (PCT) and transplantation of autologous hemopoietic cells (TAHC) in patients with lymphogranulomatosis (LGM). 27 LGM patients aged 16-42 years who have undergone TAHC after high-dose PCT (BEAM--17 patients or CBV--10 patients). 4 patients given high-dose PCT were in the first-second complete remission (CR), 7 patients--in the first partial remission (PR). Prior to TAHC, 8 patients had one, two and more relapses of LGM, and 8 patients had no remission at all. Bone marrow, hemopoietic blood cells and both were transplanted to 17, 2 and 8 patients, respectively. Mobilization of hemopoietic blood cells and stimulation of hemopoiesis after TAHC were achieved using colony-stimulating factors. The treatment resulted in CR or PR (from 6 to 95 months) in 70.4% of patients. The remission duration varied depending on the disease phase at transplantation. Four patients who underwent TAHC in PR maintained it for 13-95 months (median 47.5 months). Lasting remissions (29-59 months) were achieved in 42.9 and 37.5% of patients who underwent TAHC in the first PR or in recurrent LGM. None of the patients was in remission longer than 2 years after TAHC if high-dose PCT was conducted in advanced tumor process due to resistant LGM or inadequate previous treatment. Infectious complications lethality early after the transplantation reached 7.4%(2 patients). High-dose PCT followed by TAHC is effective in LGM if the tumor is chemosensitive.